Skip to main content
SAMJIN PHARMACEUTICAL CO.,LTD logo

SAMJIN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 005500 ISIN · KR7005500004 KO Manufacturing
Open in API
Filings indexed 249 across all filing types
Latest filing 2026-04-15 Director's Dealing
Country KR South Korea
Listing KO 005500

About SAMJIN PHARMACEUTICAL CO.,LTD

https://www.samjinpharm.co.kr/

Samjin Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's portfolio includes a wide range of over-the-counter (OTC) and prescription drugs, offered in various formulations such as oral, drop, and injectable forms. Notable products include the analgesic Gevorin, the antiplatelet agent Plavix, and the hypercholesterolemia treatment Newstatin-R. A central part of its strategy is a strong commitment to R&D, focusing on creating innovative new drugs to address diseases with high unmet medical needs. The company actively develops novel therapeutics for severe conditions, including cardiovascular, respiratory, and gastrointestinal diseases, with the goal of becoming a global pharmaceutical innovator.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a mandatory regulatory filing titled “임원ㆍ주요주주 특정증권등 소유상황보고서” filed with the Securities and Futures Commission and Korea Exchange. It details the shareholding status and transactions (acquisition/disposal) of a company executive (Park Chang Ik). This matches the definition of an insider share transaction report by directors/executives. Therefore, it should be classified as Director’s Dealing (DIRS).
2026-04-15 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a Korean-language notice titled “정기주주총회 결과” (Regular General Shareholders’ Meeting Results) dated 2026.03.24. It lists each AGM agenda item, vote outcomes (approval status and vote percentages), elected directors, dividend approvals, and related resolutions. This format matches the Declaration of Voting Results & Voting Rights Announcements category, as it provides official shareholder vote results from a general meeting.
2026-03-24 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a regulatory notification submitted to the Financial Services Commission/Korea Exchange detailing the appointment of an outside director (‘사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고’). It explicitly reports changes in the company’s board composition (outside director appointment). This matches the Board/Management Information category (MANG).
2026-03-24 Korean
기업가치제고계획(자율공시) (2026년)
Regulatory Filings Classification · 1% confidence The document is a 'Corporate Value Enhancement Plan' (기업가치 제고 계획) filed by Samjin Pharmaceutical. It outlines future financial strategies, dividend policies, and management goals. Since it does not fit into specific categories like financial reports, audit reports, or shareholder meeting materials, and is a standard regulatory disclosure regarding corporate strategy and governance, it is best classified as a general regulatory filing.
2026-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) for Samjin Pharmaceutical. It provides the audit opinion, financial highlights, and auditor information for the fiscal year ending 2025-12-31. While it contains financial data, it is a standalone regulatory disclosure regarding the audit process and results rather than the full annual report (10-K) or a simple announcement of report publication (RPA). Therefore, it fits the 'Audit Report / Information' (AR) category. FY 2025
2026-03-16 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for Samjin Pharmaceutical Co., Ltd. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and notes to the financial statements. It is not an Annual Report (10-K) as it lacks the comprehensive management discussion and analysis (MD&A) and business overview typical of a full 10-K, and it is not a report announcement (RPA) as it contains the full financial data. Therefore, it is classified as an Audit Report. FY 2025
2026-03-16 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.